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Background: The frequency of HIV dementia in a recent study of HIV individuals at the Infectious
Disease Institute in Kampala, Uganda, was 31%. Coformulated generic drugs, which include
stavudine, are the most common regimens to treat HIV infection in Uganda and many other parts
of Africa.
Objective: To evaluate the benefits and risks of stavudine-based highly active antiretroviral ther-
apy (HAART) for HIV-associated cognitive impairment and distal sensory neuropathy. The study
compared neuropsychological performance changes in HIV individuals initiating HAART for 6
months and HIV individuals receiving no treatment for 6 months. The risk of antiretroviral toxic
neuropathy as a result of the initiation of stavudine-based HAART was also examined.
Methods: At baseline, 102 HIV individuals in Uganda received neurologic, neuropsychological,
and functional assessments; began HAART; and were followed up for 6 months. Twenty-five
HIV individuals received identical clinical assessments and were followed up for 6 months.
Results: In HIV individuals, there was improvement in verbal memory, motor and psychomotor
speed, executive thinking, and verbal fluency. After adjusting for differences in sex, HIV individ-
uals demonstrated significant improvement in the Color Trails 2 test (p  0.025) compared with
HIV individuals. Symptoms of neuropathy developed in 38% of previously asymptomatic HIV
patients after initiation of the stavudine-based HAART.
Conclusions: After the initiation of highly active antiretroviral therapy (HAART) including stavu-
dine, HIV individuals with cognitive impairment improve significantly as demonstrated by im-
proved performance on a test of executive function. However, peripheral neurotoxicity occurred
in 30 patients, presumably because of stavudine-based HAART, suggesting the need for less
toxic therapy. Neurology® 2009;72:165–170
GLOSSARY
AVLT  Auditory Verbal Learning Test; CES-D  Center for Epidemiologic Studies–Depression Scale; D-drug 
dideoxynucleoside antiretroviral drug; GEE  generalized estimating equation; GP  Grooved Pegboard test; HAART 
highly active antiretroviral therapy; HIV-SN  HIV-associated sensory neuropathy; IHDS  International HIV Dementia Scale;
MSK  Memorial Sloan-Kettering; NA  not applicable; NS  not significant; SDMT  Symbol Digit Modalities Test; UCLA 
University of California-Los Angeles; WHO  World Health Organization.
The majority of HIV cases globally, an estimated 25 million people, are in sub-Saharan Africa.1
HIV-1–associated dementia complex (HIV dementia) is characterized by disabling cognitive,
behavioral, and motor dysfunction.2 HIV-associated sensory neuropathies (HIV-SNs) are an-
other common neurologic manifestation of advanced HIV infection seen in approximately
35% of HIV-infected patients.3-5 HIV-SNs can be caused by HIV infection itself as a distal
symmetric polyneuropathy or by exposure to dideoxynucleoside antiretroviral drugs (D-drugs),
which include d4T (stavudine) as an antiretroviral toxic neuropathy. The frequency of HIV
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dementia, the most severe form of HIV-
associated neurocognitive disorders, in a re-
cent study of ambulatory HIV patients in
an Infectious Disease Clinic in Kampala,
Uganda, was 31%.6 The frequency of HIV-SN
in this same study was 32%.
Highly active antiretroviral therapy (HAART)
can improve cognitive performance in some
patients with HIV dementia in the United
States.7-9 In a pilot study of 23 HIV individ-
uals in Uganda, HAART also was associated
with improvement in neuropsychological test
performance.10 This pilot study was without a
control group so that the study was limited
by the possibility of “practice effects.” Fur-
thermore, it is possible that HAART may
improve peripheral neuropathy in some in-
dividuals, whereas it is a recognized toxicity
in others.11
Generic drugs are the most commonly
used antiretroviral drugs in sub-Saharan Af-
rica. Triommune is a coformulation of stavu-
dine, lamivudine, and nevirapine. Because of
cost and availability, it is the most frequent
generic regimen prescribed.
The objective of this study was to evaluate
the benefits and risks of stavudine-based
HAART for HIV-associated neurologic com-
plications, namely HIV-associated cognitive
impairment and HIV-SN in Uganda. Specifi-
cally, the study compared neuropsychological
test performance changes in HIV individu-
als initiating Triommune for 6 months and
HIV individuals receiving no treatment for
6 months. The risk of antiretroviral toxic neu-
ropathy as a result of the initiation of Triom-
mune was also examined.
METHODS Participants. The study was conducted, from
September 2005 to January 2007, with 102 HIV individuals
at the Infectious Disease clinic in Mulago Hospital and with 25
HIV individuals from the AIDS Information Center in Kam-
pala, Uganda.12 The study was approved by the institutional re-
view boards and ethical standards committees at Johns Hopkins
University in Baltimore, Maryland, and Makerere University in
Kampala, Uganda. Written patient consent was obtained from
all individuals. All HIV subjects had a documented negative
ELISA HIV-1 test result. HIV individuals in the clinic were
chosen to receive HAART using the following inclusion criteria:
advanced HIV infection with a CD4 lymphocyte count 200
cells/L, attendance of at least two clinic visits in the past 6
months, residence within a 20-km radius of Kampala, antiretro-
viral drug naive, performance on a screening test for HIV de-
mentia (International HIV Dementia Scale [IHDS] score 10)
suggestive of HIV-associated cognitive impairment,13 and ability
to provide written informed consent. Exclusion criteria included
age less than 18 years, an active or known past CNS opportunis-
tic infection, fever 37.5°C, a history of a chronic neurologic
disorder, active psychiatric disorder, alcoholism, physical deficit
(e.g., amputation), severe functional impairment (Karnofsky
Performance Scale score 50),14 or severe medical illness that
would interfere with the ability to perform the study evaluations.
The evaluations were translated into the local language,
Luganda.
Clinical assessments. HIV individuals received clinical as-
sessments using standardized questionnaires assessing demo-
graphic information, including primary language and reading
abilities; medical, psychiatric, and neurologic history, including
an assessment of peripheral neuropathy symptoms; and a neuro-
logic examination, including assessments of vibration and pin
sensation, limb strength and coordination, and deep tendon re-
flexes. The neurocognitive assessment included the IHDS13 and
a full neuropsychological test battery. The neuropsychological
testing battery included the World Health Organization
(WHO)–University of California-Los Angeles (UCLA) Audi-
tory Verbal Learning Test (AVLT) for verbal memory15; the
Timed Gait, Finger Tapping, and Grooved Pegboard tests to
assess motor performance; the Symbol Digit Modalities test16
and the Color Trails test15 to assess psychomotor speed and exec-
utive functioning performance; Digit Span Forward and Back-
ward to assess attention; and the category naming test to assess
verbal fluency. The functional assessment included the Karnof-
sky Performance Scale.14 These assessments were used to assign a
Memorial Sloan-Kettering (MSK) dementia stage of 0, 0.5, or
1 by a consensus conference including a neurologist, a psychi-
atrist, and a neuropsychologist.17
All HIV subjects received a baseline CD4 lymphocyte
count. Follow-up CD4 counts were obtained at 3 and 6 months
after baseline. Plasma and CSF HIV RNA as well as neuroimag-
ing were not available in this study.
HIV individuals received identical clinical assessments ex-
cept for the absence of CD4 lymphocyte counts. HIV individ-
uals were also followed up for 6 months.
Antiretroviral treatment. After the baseline visit, all of the
HIV subjects began Triommune (stavudine, lamivudine, and
nevirapine). HIV individuals received no treatment.
Data analysis. For each neuropsychological test, a Z score was
calculated using age- and education-adjusted normative data ob-
tained from 100 HIV individuals in Uganda.6 Distributional
tests have confirmed that the resultant Z scores follow a normal
distribution, and scores are summarized as mean (SE). To ac-
count for loss-to-follow-up, longitudinal changes in the mean Z
score for each neuropsychological test were evaluated at 3 and 6
months using generalized linear models for handling nonignor-
able dropouts for continuous outcomes.18 Statistical inference for
the model parameters was based on generalized estimating equa-
tions (GEEs).19 The GEE model included HIV serostatus, study
visit, and the interaction between HIV serostatus and study visit
as important parameters. Significance of the interaction term
was taken as inferential evidence of a difference in longitudinal
performance between the HIV and HIV groups. Type I er-
ror rates were adjusted for multiple comparisons using a Bonfer-
roni correction. Distributional tests have confirmed that CD4
count, IHDS screening test, and Karnofsky Performance Scale
scores did not follow a normal distribution, and scores were sum-
marized as median and interquartile range (25th and 75th per-
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centiles). Longitudinal changes in these measures were evaluated
using a nonparametric one-way analysis of variance.
RESULTS The demographics for the 102 HIV
subjects and 25 HIV subjects are summarized in
table 1. The HIV subjects [mean (SD) age  34.2
(6.4) years] were slightly older than the HIV sub-
jects [mean (SD) age  30.3 (4.0) years] (p 
0.004). There were no differences in level of educa-
tion between the two groups. The HIV group
(28% male) had a greater proportion of women than
the HIV group (60% male) (p  0.003). The
HIV subjects in our study are representative of the
demographics of HIV infection in Uganda.
Using the inclusion criteria of an IHDS score 10
suggesting HIV-associated neurocognitive disorders,
the frequency of HIV dementia at baseline was high,
with 33% presenting to the ambulatory clinic with mild
HIV dementia (MSK dementia stage 1) and 7% pre-
senting with moderate HIV dementia (MSK dementia
stage 2). None of the HIV individuals had impair-
ment on their neuropsychological testing to consider a
diagnosis of dementia. The HIV individuals also had
more functional impairment at baseline as measured by
the Karnofsky score [HIV group Karnofsky mean
(SD)  84 (8.5) vs HIV group Karnofsky mean
(SD)  98 (4.1); p  0.001].
The follow-up rates for the HIV and HIV
subjects were excellent. Among the HIV patients,
92% returned for their 6-month follow-up visit.
Among the HIV subjects, 84% returned for their
6-month follow-up visit. There was improvement in
the mean CD4 count among the HIV subjects at
both 3 and 6 months after the initiation of HAART.
The mean CD4 count improved from 129 at base-
line to 268 at 3 months (p  0.001) and to 272 at 6
months (p  0.01).
Neurocognitive improvement with HAART. As shown
in the figure 1, improvements in the MSK HIV de-
mentia stage were noted among the HIV subjects
after 6 months of HAART. After 3 months, 23% of
the HIV individuals had mild HIV dementia (MSK
dementia stage 1) and 3% had moderate HIV de-
mentia (MSK dementia stage 2). After 6 months,
13% of the HIV individuals had mild HIV de-
mentia (MSK dementia stage 1) and 3% had moder-
ate HIV dementia (MSK dementia stage 2) (p  0.001).
Table 2 shows the changes in the mean neuropsy-
chological test performance for each of the neuropsy-
chological tests after 3 and 6 months of HAART
among the HIV subjects. Compared with baseline,
improvement was seen in tests of verbal memory
(WHO–UCLA AVLT total score and delayed recall
at 3 and 6 months), psychomotor speed and execu-
tive functioning (Color Trails 1 and 2 at 3 and 6
months, Symbol Digit Modalities test at 6 months
only), motor performance (Timed Gait and Grooved
Pegboard dominant hand at 6 months only, Grooved
Pegboard nondominant hand and Finger Tapping at
3 and 6 months), and verbal fluency (category nam-
ing at 3 and 6 months).
Table 3 shows the changes in the mean neuropsy-
chological test performance for each of the neuropsy-
chological tests after 6 months among the untreated
HIV subjects. Compared with baseline, among the
HIV subjects, improvement was seen in a test of
motor speed (Grooved Pegboard nondominant hand
at 3 months, Grooved Pegboard dominant hand at 6
months) and psychomotor speed (Color Trails 1 at 6
months only). Also, there was borderline improve-
ment in tests of verbal memory [AVLT total score
(p  0.09) and delayed recall (p  0.08) at 6
months]. No other neuropsychological test showed
improvement compared with baseline among the
HIV subjects.
Compared with the HIV subjects, HIV sub-
jects showed improvement on the Color Trails 2 test
(p  0.02) after adjusting for differences in sex (fig-
Table 1 Demographics of HIV and HIV individuals
HIV (n  102) HIV (n  25) p Value
Age, mean (SD), y 34.2 (6.4) 30.3 (4.0) 0.004
Education, mean (SD), y 9.1 (4.3) 10.3 (4.2) NS
Male, n (%) 29 (28) 15 (60) 0.003
CD4 count, mean (SD) 129 (79.0) NA
Karnofsky score, mean (SD) 84 (8.5) 98 (4.1) 0.001
MSK HIV dementia stage, baseline, n (%)
0  no impairment 12 (12) NA
0.5  equivocal/subclinical 48 (48) NA
1  mild dementia 33 (33) NA
2  moderate dementia 7 (7) NA
NS  not significant; NA  not applicable; MSK  Memorial Sloan-Kettering.
Figure 1 Memorial Sloan-Kettering HIV dementia stage changes after 3 and
6 months of highly active antiretroviral therapy
0  Memorial Sloan-Kettering (MSK) 0 (normal cognitive function); 0.5  MSK 0.5 (equivo-
cal symptoms or signs without impairment in capacity to perform activities of daily living);
1  MSK 1 (mild HIV dementia); 2  MSK 2 (moderate HIV dementia).
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ure 2). Other tests, e.g., WHO–UCLA AVLT,
showed trends for greater improvement among the
HIV subjects compared with the HIV subjects,
but this difference was not significant.
Functional improvement with HAART. There was im-
provement in the functional performance (Karnofsky
scale) at both 3 and 6 months after the initiation of
HAART among HIV subjects. The mean Karnof-
sky score improved from 84 at baseline to 87 at 3
months (p  0.002) and to 89 at 6 months (p 
0.001). A Karnofsky score of 80 indicates an individ-
ual who is able to do normal activity with effort but
shows some disease symptoms or signs. A Karnofsky
score of 90 indicates an individual who is able to do
normal activity without effort but shows minor dis-
ease symptoms or signs.
Neuropathy changes over time. Among the HIV
subjects, 37% had foot numbness at baseline.20 Signs
of neuropathy (loss of vibration or pinprick sensa-
tion, decreased or absent ankle reflexes) were present
in 43% of the HIV subjects at baseline. In con-
trast, only 1 (4%) of the HIV controls had foot
numbness at baseline, and 1 (4%) of the HIV con-
trols had signs of neuropathy at baseline. After 6
months, 54% of the HIV subjects had numbness
in the feet. Symptoms of neuropathy were described
in 38% (n  30) of previously asymptomatic HIV
patients after initiation of the stavudine-based
HAART. Signs of neuropathy were detected in 31%
(p  0.03) of the HIV individuals who did not
have signs at baseline after initiation of HAART.
There were no differences in the age, education, sex,
or CD4 count among asymptomatic HIV patients
who developed symptoms of neuropathy and asymp-
tomatic HIV patients who did not develop symp-
toms of neuropathy after initiation of the stavudine-based
HAART. Similarly, there were no differences in the
age, education, sex, or CD4 count among HIV
patients without signs of neuropathy at baseline who
developed signs of neuropathy and HIV patients
who never developed signs of neuropathy after initia-
tion of the stavudine-based therapy. In contrast, only
1 (4%) of the HIV controls had an increase in
neuropathy symptoms from baseline, and only 1
(4%) had an increase in neuropathy signs from base-
line.
After the initiation of the stavudine-based
HAART, some HIV subjects had improvement in
neuropathy symptoms and signs present at baseline.
Among HIV subjects with foot numbness at base-
line, 22% no longer had numbness after 6 months of
the stavudine-based HAART. Among HIV sub-
jects with signs of neuropathy at baseline, 23% no
longer had neuropathy signs after 6 months of the
stavudine-based HAART.
DISCUSSION The results from this study support
the clinical benefit of HAART for stavudine-based
therapy in HIV individuals in Uganda. After the
initiation of HAART, HIV individuals had im-
provement in their level of immune suppression with
increased CD4 counts. HIV individuals had im-
provement in their overall functional performance as
measured by the Karnofsky scale. HIV individuals
also had improvements in their neurocognitive per-
formance in tests of verbal memory, psychomotor
and motor speed performance, executive function-
ing, and verbal fluency similar to the results of a prior
Table 2 Neuropsychological test performance at baseline and 3 and 6




score* (n  102)
3-Month Z




score* (n  95)
p
Value†
AVLT total score 1.2 (0.1) 0.4 (0.1) 0.001 0.1 (0.2) 0.001
AVLT delayed recall 1.2 (0.1) 0.4 (0.2) 0.003 0.1 (0.1) 0.001
Color Trails 1 1.7 (0.3) 0.7 (0.2) 0.001 0.4 (0.3) 0.001
Color Trails 2 2.8 (0.3) 1.9 (0.4) 0.001 1.3 (0.2) 0.001
SDMT 0.8 (0.1) 0.5 (0.1) NS 0.3 (0.1) 0.002
GP, dominant hand 0 (0.2) 0.2 (0.1) NS 0.4 (0.1) 0.014
GP, nondominant
hand
0.7 (0.2) 0.1 (0.1) 0.001 0.3 (0.1) 0.001
Finger tapping 1.0 (0.1) 0.5 (0.1) 0.001 0.5 (0.1) 0.002
Timed gait 2.7 (0.3) 2.3 (0.3) NS 1.8 (0.3) 0.028
Verbal fluency 0.4 (0.4) 0.1 (0.1) 0.007 0 (0.1) 0.001
*Mean (SE).
†Compared with performance at baseline.
HAART  highly active antiretroviral therapy; AVLT  Auditory Verbal Learning Test; SDMT 
Symbol Digit Modalities Test; NS  not significant; GP  Grooved Pegboard test.
Table 3 Neuropsychological test performance at baseline and 3 and 6




score* (n  25)
3-Month Z




score* (n  25)
p
Value†
AVLT total score 0.4 (0.3) 0.4 (0.4) NS 0.2 (0.2) NS
AVLT delayed recall 0.6 (0.2) 1.1 (0.6) NS 0.1 (0.2) NS
Color Trails 1 0.3 (0.3) 0.2 (0.3) NS 0.8 (0.2) 0.006
Color Trails 2 0.8 (0.3) 0.4 (0.4) NS 0.4 (0.3) NS
SDMT 0.4 (0.3) 0.2 (0.3) NS 0.4 (0.3) NS
GP, dominant hand 0.3 (0.3) 0.9 (0.2) NS 0.8 (0.2) 0.032
GP, nondominant
hand
0.1 (0.2) 0.7 (0.2) 0.011 0.6 (0.2) NS
Finger tapping 0.0 (0.2) 0.1 (0.3) NS 0.1 (0.2) NS
Timed gait 1.5 (0.5) 0.4 (0.5) NS 1.7 (0.4) NS
Verbal fluency 0.0 (0.2) 0.2 (0.3) NS 0.4 (0.3) NS
*Mean (SE).
†Compared with performance at baseline.
HAART  highly active antiretroviral therapy; NS  not significant; AVLT  Auditory Verbal
Learning Test; SDMT  Symbol Digit Modalities Test; GP  Grooved Pegboard test.
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pilot study in Uganda evaluating the effect of
HAART on neurocognitive performance.10
The neuropsychological test improvement among
HIV individuals is likely due to a combination of
both HAART-associated improvements in immune
suppression and neurocognitive function as well as
practice effects. Compared with HIV individuals,
HIV individuals showed greater improvement in
Color Trails 2, a test of executive functioning, sug-
gesting that practice effects alone cannot account for
the improvements seen in executive functioning.
However, a ceiling effect for performance on this
test, where the HIV subjects could not improve
significantly from baseline normal function, could
have limited the learning effects relevant to the con-
trol group. Other cognitive domains, e.g., verbal
memory, showed trends for greater improvement
among HIV individuals compared with HIV in-
dividuals. However, the sample size of the study may
not have been large enough to detect a difference
between the two groups. In addition, it is possible
that some of the neurocognitive impairment among
the HIV individuals at baseline may have been due
to confounding factors other than HIV infection it-
self, and thus unlikely to improve with HAART.
The prevalence of neuropathy symptoms and
signs at baseline in our study is similar to the preva-
lence of neuropathy symptoms and signs in Western
countries among HIV patients with advanced
immunosuppression,3-5 because the mean CD4
count of our HIV cohort was 129 cells. Stavudine-
based HAART is also associated with some measur-
able neurologic morbidity. In Western countries,
D-drug based HAART is rarely used now because of
the risk of peripheral neuropathy. In our study in
Uganda among HIV patients without peripheral
neuropathy at baseline, 31% to 38% of these patients
developed either symptoms or signs of neuropathy
during the study. The onset of the symptomatic neu-
ropathy experienced after starting therapy was
prompt within the first 3 months of the trial, sug-
gesting that stavudine may have been the cause of the
neuropathy or stavudine decreased the threshold for
developing an HIV-related neuropathy. The severity
of these symptoms did not lead to HAART discon-
tinuation in any of these patients. However, the
study duration was only 6 months. At present, it is
unclear whether a cumulative toxicity of stavudine
over longer periods of treatment might result in a
greater proportion affected or more severe neuropa-
thy in those taking this therapy. Future studies of
neuropathy should include a more extensive period
of follow-up.
There are limitations to the study. The study was
conducted among HIV patients from an urban set-
ting in Kampala, Uganda, which is likely to be repre-
sentative of the urban HIV community in Uganda.
However, it may not necessarily reflect the HIV
population in rural Uganda.
All study participants received a screening test for
depression symptomatology, the Center for Epide-
miologic Studies–Depression Scale (CES-D).21 At
baseline, the mean CES-D score for the HIV
group was 18.1 (SD 11.4). Thus, some patients may
have had major depression. However, a psychiatrist
on site evaluated any patient in which an active psy-
chiatric condition was a concern.
HIV subtypes D and A are the predominant sub-
types in Uganda, whereas subtype C is the predomi-
nant subtype in southern Africa. If HIV subtype has
an effect on HIV neuropathogenesis, our results in
Uganda may not necessarily reflect the HIV popu-
lation throughout Africa.
HIV patients did not receive either neuroimag-
ing or CSF examinations to rule out another CNS
disease as the cause for an individual’s cognitive im-
pairment. Other infectious diseases, such as tubercu-
losis, syphilis, or malaria, or malnutrition could have
contributed to the cognitive impairment in our study
participants. However, all HIV patients did receive
a detailed neurologic history and examination (in-
cluding an evaluation of fever, headache, neck stiff-
ness, and focal abnormalities). Any HIV patient
with a suspected CNS opportunistic infection or
neoplasm was excluded from the study.
The neuropsychological tests that showed the
largest improvement among the HIV patients were
the tests that had the largest baseline Z score deficits.
Thus, regression to the mean may have been a con-
tributing factor for some of the neurocognitive im-
provement seen among the HIV patients.
HIV individuals demonstrated greater im-
provement in functional performance compared
with HIV individuals. However, the HIV indi-
viduals had normal functional performance in gen-
Figure 2 Color Trails 2 changes over 6 months
Case  HIV individual; control  HIV individual. Y-axis corresponds to the Z score on the
Color Trails 2 test.
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eral, so this group had little capacity for further
improvement.
The cause of the neuropathy could not be fully
determined due to the design of the study. A screen-
ing question for diabetes was included, and two
HIV individuals reported a history of diabetes.
Screening tests for other causes of neuropathy and
electrophysiological studies were not available in
Uganda. Ideally, a group of HIV individuals with
the same inclusion criteria at study entry who were
not on a stavudine-based regimen could have been
evaluated, but this group of patients did not exist at
the time of the study.
HAART is a lifesaving therapy for HIV patients
with advanced immunosuppression in sub-Saharan
Africa, and if a patient meets clinical criteria,
HAART should be initiated without delay. If no
other antiretroviral drug options are available,
stavudine-based HAART can provide benefit with
respect to immune system restoration and improve-
ment in executive functioning in HIV individuals
with neurocognitive impairment. However, this
study provides data demonstrating that peripheral
neurotoxicity is a significant problem from stavudine-
based HAART, and if possible, alternative antiretro-
viral drug combinations should be provided. It is
anticipated that future trends will have decreased use
of stavudine-based therapies in resource limited
countries. Additional resources to provide HAART
regimens without stavudine would provide a great
benefit by preventing a potential increase in the prev-
alence of painful peripheral neuropathy among mil-
lions of HIV individuals who will need HAART
within the next several years in sub-Saharan Africa.
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